In the present study, advanced EGFR‐mutant NSCLC patients with acquired T790M mutation and EGFR amplification following resistance to first‐generation EGFR‐TKI demonstrated improved PFS compared to those without EGFR amplification. This evidence concerns the gene EGFR and non-small cell lung carcinoma.